Molecular data
| Molecular formula | C62H98N16O22 |
|---|---|
| Molecular weight | 1419.53 Da |
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Sequence length | 15 residues |
| CAS / identifier | 137525-51-0 |
| Physical form | Lyophilized powder |
| Available sizes | 10mg, 20mg |
How it works
Angiogenesis & Vascular Support
BPC-157 upregulates vascular endothelial growth factor (VEGF) expression, promoting new blood vessel formation and enhancing blood supply to injured tissue in preclinical models.
- Promotes blood vessel formation (angiogenesis)
- Enhances VEGF receptor expression
- Modulates nitric oxide signaling (NO system)
GHR Upregulation
Research demonstrates BPC-157 enhances growth hormone receptor expression in tendon fibroblasts by 7× within 3 days, supporting tissue repair signaling cascades.
- 7× growth hormone receptor upregulation
- Enhances tendon fibroblast viability
- Supports collagen synthesis signaling
Tissue Protection & Repair
BPC-157 demonstrates broad cytoprotective properties across multiple organ systems in animal studies, with particular relevance to gastrointestinal and musculoskeletal tissues.
- Gastric mucosal protection
- Accelerated wound closure in animal models
- Neuroprotective properties observed
What the research shows
Tendon & Ligament
Accelerated healing of Achilles tendon, MCL, and rotator cuff injuries in rat models with improved collagen fiber organization.
Chang et al. 2014
Gut Protection
Cytoprotective effects against NSAID-induced damage, alcohol lesions, and inflammatory bowel disease models.
Sikiric et al. 2011
Brain & Nervous System
Demonstrated neuroprotective effects in traumatic brain injury and peripheral nerve damage models with improved recovery markers.
Sikiric et al. 2016
Blood Vessel Repair
Promotes angiogenesis and accelerates blood vessel healing after surgical transection in animal models via NO system modulation.
Sikiric et al. 2019
Specification
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
|---|---|
| Molecular Weight | 1419.53 Da |
| Molecular Formula | C₆₂H₉₈N₁₆O₂₂ |
| Form | Lyophilized powder (5mg) |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage (lyophilized) | -20°C for long-term stability |
| Storage (reconstituted) | 2–8°C, use within 30 days |
| Solubility | Bacteriostatic water for reconstitution |
| COA | Included with every order |
Frequently asked questions
What is BPC-157 and where does it come from?
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino acid peptide derived from a larger protein found in human gastric juice. It was discovered during research at the University of Zagreb, Croatia, and has been studied extensively in animal models for its tissue-protective and regenerative properties.
Is BPC-157 FDA approved?
No. BPC-157 is not approved by the FDA or any regulatory agency for human use. It is classified as an unapproved drug. The FDA has issued warnings about BPC-157 being found in compounded products and dietary supplements. Only one Phase I clinical trial has been registered, and no Phase 2 or 3 trials have been completed.
What does the research show about BPC-157?
Preclinical research (animal studies) has shown BPC-157 may accelerate healing of tendons, ligaments, muscles, and bones; protect the gastrointestinal tract from ulcers and inflammation; have neuroprotective effects in brain injury models; and promote blood vessel formation. All findings are from animal studies — no human clinical data exists.
How is BPC-157 used in research settings?
In preclinical research, BPC-157 is typically reconstituted in bacteriostatic water and administered via intraperitoneal injection in rodent models. Research dosages range from 10 mcg/kg to 10 mg/kg depending on the study protocol and target tissue being investigated.
What are the safety concerns with BPC-157?
No lethal dose was reached in preclinical toxicology studies, and no significant adverse effects have been reported in published research. However, BPC-157 has never completed human clinical trials, so its safety profile in humans is unknown. It should only be used for in vitro laboratory research.
How should BPC-157 be stored?
Lyophilized (powder) form should be stored at -20°C for long-term stability. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 30 days. BPC-157 is remarkably stable — it resists hydrolysis, enzymatic degradation, and gastric acid.
Literature
- PubMed Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract
- PubMed Pentadecapeptide BPC 157 enhances growth hormone receptor expression in tendon fibroblasts
- PubMed BPC 157 and NO system
- PubMed Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications
For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.